Applying Shear Wave Elastography for Adjunct Steroid on Tuberculous Lymphadenitis

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · May 15, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how a special imaging technique called shear wave elastography can help understand the effects of corticosteroid treatment in patients with tuberculous lymphadenitis, a condition caused by tuberculosis that leads to swollen lymph nodes. The researchers want to see if adding steroids can help reduce a particular reaction that sometimes happens during treatment, known as paradoxical upgrading, and they will also explore whether certain markers in the body can predict this reaction.

To be eligible for this trial, participants must be diagnosed with tuberculous lymphadenitis based on specific tests, such as a culture or a biopsy showing signs of infection. Unfortunately, people under 18 years old or those who have already had surgery for this condition cannot participate. During the trial, participants will have their medical information collected from the start of treatment until after they finish. This study is actively recruiting participants, so if someone meets the criteria and is interested, they can reach out to learn more about joining.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants diagnosed of tuberculous lymphadenitis.
• * The diagnosis of tuberculous lymphadenitis must qualify any of the following criteria:
• • 1. microbiological evidence (culture or nucleic acid amplification test)
• • 2. histology specimen featuring caseating granulomatous inflammation with acid-fast bacilli on smear, or clinical response to anti-tuberculosis therapy.
• Exclusion Criteria:
• • Participants with age \< 18 years
• • Diagnoses based on histologic report turned out to be non-tuberculosis mycobacterial infection
• • The tuberculous lymphadenitis involved was surgically removed, without available target to be monitored
• • Participant under systemic (oral or parenteral) steroid therapy.
• • Participant with active hepatitis B virus infection
• • Participant reluctant to be enrolled in the trial